We are live on ! Find out more
MP

Mangrove Partners Portfolio holdings

AUM $1.24B
1-Year Est. Return 41.74%
This Fund
S&P 500
This Quarter Est. Return
-27.66%
1 Year Est. Return
+41.74%
3 Year Est. Return
+169.22%
5 Year Est. Return
+150.23%
10 Year Est. Return
+417.9%
AUM
$725M
AUM Growth
+$41.8M
Cap. Flow
+$440M
Cap. Flow %
60.69%
Top 10 Hldgs %
66.05%
Holding
87
New
15
Increased
15
Reduced
12
Closed
10

Top Buys

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$292M
2
PCG icon
PG&E
PCG
+$43M
3
SMCI icon
Super Micro Computer
SMCI
+$33.7M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$24.9M
5
TGTX icon
TG Therapeutics
TGTX
+$15.7M

Top Sells

Rank Stock Value
1
NIHD
NII Holdings, Inc. Common Stock
NIHD
+$17.8M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$7.83M
3
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$5.93M
4
PDCE
PDC Energy, Inc.
PDCE
+$5.77M
5
GYRE icon
Gyre Therapeutics
GYRE
+$4.65M

Sector Composition

Rank Sector Weight
1 Healthcare 16.73%
2 Energy 8.12%
3 Communication Services 7.53%
4 Materials 5.91%
5 Industrials 4.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DPHCW
76
DELISTED
DiamondPeak Holdings Corp. Warrant
DPHCW
$30K ﹤0.01%
66,666
– –
THCAW
77
DELISTED
Tuscan Holdings Corp. II Warrant
THCAW
$25K ﹤0.01%
100,000
– –
GYRE icon
78
Gyre Therapeutics
GYRE
$648M
– –
-91,017
Closed -$4.65M
SPNT icon
79
SiriusPoint
SPNT
$2.78B
– –
-100,201
Closed -$1.05M
HCCOU
80
DELISTED
Healthcare Merger Corp. Units
HCCOU
– –
-300,000
Closed -$3.1M
DEACW
81
DELISTED
Diamond Eagle Acquisition Corp. Warrant
DEACW
– –
-33,333
Closed -$80K
FOMX
82
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
– –
-1,779,448
Closed -$5.93M
CTACW
83
DELISTED
ChaSerg Technology Acquisition Corp. Warrant
CTACW
– –
-275,000
Closed -$605K
DERM
84
DELISTED
Dermira, Inc.
DERM
– –
-221,640
Closed -$3.36M
TKKSR
85
DELISTED
TKK Symphony Acquisition Corporation Right
TKKSR
– –
-350,000
Closed -$88K
TKKSW
86
DELISTED
TKK Symphony Acquisition Corporation Warrant
TKKSW
– –
-350,000
Closed -$21K
NIHD
87
DELISTED
NII Holdings, Inc. Common Stock
NIHD
– –
-8,200,064
Closed -$17.8M
1 2 3
4

Similar funds

GX
Greylock XIV Menlo Park, California $1.24B AUM
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
HTHT
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.24B AUM 16.47% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return

Mangrove Partners's Q1 2020 Portfolio in Review

As of Q1 2020, Mangrove Partners held 87 positions worth $725M, up 6.1% from $683M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Mangrove Partners deployed $440M of net new capital in Q1 2020, opening 15 new positions and adding to 15 existing holdings. Its largest new stake was iShares Russell 2000 ETF: 1,961,000 shares worth $224M.

By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 17% a quarter earlier, followed by Energy and Communication Services.

On the sell side, the largest reduction was Iovance Biotherapeutics, an estimated $7.83M trimmed.

  • Mangrove Partners's largest Q1 2020 buy was iShares Russell 2000 ETF: 1,961,000 shares worth $224M.
  • Mangrove Partners added most to PG&E in Q1 2020, an estimated $43M increase.
  • Mangrove Partners's biggest Q1 2020 reduction was Iovance Biotherapeutics, cutting an estimated $7.83M.
  • Mangrove Partners fully exited NII Holdings, Inc. Common Stock in Q1 2020, selling an estimated $17.8M.
  • Mangrove Partners's ten largest holdings make up 66% of its $725M portfolio in Q1 2020.
  • Mangrove Partners opened 15 new positions and closed 10 in Q1 2020.
  • Mangrove Partners's portfolio value rose 6.1% quarter-over-quarter to $725M.

Based on Mangrove Partners's 13F filing for Q1 2020, filed 15 May 2020.